Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:36:21.733Z.
Calculation as of: 2026-10-06T15:36:21.733Z.
Quote observation: 2026-10-06T15:35:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3e31615b66e5acc6c2b7b3f8a521ec69124b31f47383f0f9627e8176a83f275d
PE RATIO
N/A
Market Cap
$4.69B
PE Ratio
93.30
TTM Avg
202.48
3Y Avg
202.48
5Y Avg
202.48
Market Cap
$4.44B
PE Ratio
12.77
TTM Avg
20.82
3Y Avg
83.80
5Y Avg
77.36
Market Cap
$4.43B
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Definium Therapeutics, Inc. (DFTX) | $4.74B | N/A | N/A | N/A | N/A |
| LifeStance Health Group, Inc. (LFST)vs › | $4.69B | 93.30 | 202.48 | 202.48 | 202.48 |
| Option Care Health, Inc. (OPCH)vs › | $4.64B | 23.31 | 21.05 | 22.44 | 28.91 |
| BillionToOne, Inc. (BLLN)vs › | $4.62B | 161.91 | 879.32 | 879.32 | 879.32 |
| Oruka Therapeutics, Inc. (ORKA)vs › | $4.88B | N/A | N/A | N/A | N/A |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.91B | N/A | N/A | N/A | N/A |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.93B | N/A | N/A | N/A | N/A |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.44B | 12.77 | 20.82 | 83.80 | 77.36 |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.43B | N/A | N/A | N/A | N/A |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.08B | 35.19 | 36.67 | 43.17 | 53.01 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$35.70
Forward EPS (Est.)
$-3.17
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
